In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Synthetic Biologics (SYN - Research Report), with a price target of $4.00. The company's shares closed yesterday at $1.07.McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Moleculin Biotech. According to TipRanks, McCarthy has an average return of -44.1% and an 8.84% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Synthetic Biologics with a $14.00 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $4.
https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-synthetic-biologics-syn?utm_source=advfn.com&utm_medium=referral
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Déc 2022 à Jan 2023 Plus de graphiques de la Bourse Synthetic Biologics
Synthetic Biologics (AMEX:SYN)
Graphique Historique de l'Action
De Jan 2022 à Jan 2023 Plus de graphiques de la Bourse Synthetic Biologics